Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients-Reference-Cited by-同舟云学术

Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients

Published:2020-11-03 Issue:5 Volume:61 Page:614-627
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Luo Man (Melody)¹,Usmani Saad Z.²,Mateos Maria‐Victoria³,Nahi Hareth⁴,Chari Ajai⁵,San‐Miguel Jesus⁶,Touzeau Cyrille⁷,Suzuki Kenshi⁸,Kaiser Martin⁹,Carson Robin¹,Heuck Christoph¹,Qi Ming¹,Zhou Honghui¹,Sun Yu‐Nien¹,Parasrampuria Dolly A.¹

Affiliation:

1. Janssen Research & Development LLC Spring House Pennsylvania USA

2. Levine Cancer Institute/Atrium Health Charlotte North Carolina USA

3. University Hospital of Salamanca/IBSAL/Cancer Research Center‐IBMCC (USAL‐CSIC) Salamanca Spain

4. Department of Medicine Division of Hematology Karolinska Institute Karolinska University Hospital at Huddinge Stockholm Sweden

5. Icahn School of Medicine at Mount Sinai New York New York USA

6. Clínica Universidad de Navarra‐CIMA IDISNA CIBERONC Pamplona Spain

7. Hematology Department University Hospital Hôtel‐Dieu Nantes France

8. Department of Hematology Japanese Red Cross Medical Center Tokyo Japan

9. The Institute of Cancer Research and the Royal Marsden Hospital London UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1771

Reference41 articles.

1. National Cancer Institute.SEER Cancer Stat Facts: Myeloma.https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed August 17 2020.

2. Cancer Research UK.Myeloma statistics.https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/myeloma. Accessed August 17 2020.

3. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

4. Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

5. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential Opportunities of Modeling Bioavailability for Monoclonal Antibodies: An Overview of mAbs and the current challenges of mAb development;2024-04-18

2. Modeling the subcutaneous pharmacokinetics of antibodies co‐administered with rHuPH20;Clinical and Translational Science;2024-04

3. Daratumumab Treatment for “Truly Frail” Elderly Myeloma Patients;Life;2024-03-15

4. Use of daratumumab drug formulation for subcutaneous administration in multiple myeloma therapy: Literature review and clinical observation;MD-Onco;2023-12-06

5. Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume;mAbs;2023-11-27